Skip to main content

Catalyst Calendar

Scope
Catalyst

Tue, Oct 6, 2026

1 updates
REGN
7:00 AM

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation Final Phase 2 analysis explores potential of Libtayo before surgery (neoadjuvant treatment) for patients with

Presentation / Abstract • Phase 3ESMO poster presentations Sat, Oct 24, 2026, 12:00 PM CETregeneron.com

Thu, Oct 1, 2026

2 updates
REGN
11:35 AM

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy Results presented in a late-breaking plenary session at IGCS demonstrated a 73% objective response rate and 11-month median progression-free

Presentation / Abstract • Phase 1/2presentation Thu, Oct 1, 2026, 11:35 AM EDTregeneron.com